fda bans compounded semaglutide and tirzepatide US warns online vendors selling unapproved weight-loss drugs FDA moves to remove GLP-1

Can J Physiol Pharmacol 103, 369377 (2025)

What are the current and emerging options for the treatment of obesity

Limited recent data exist on prescribing patterns and patient characteristics for GLP-1 RA medications, whether used as anti-diabetic medication (ADM) for patients with type 2 diabetes and/or used as an anti-obesity medication (AOM) for patients with overweight or obesity

Urine samples were collected +1 h, +2h (urine only), +4h, +6h after intake, and in the morning of the subsequent two days (+24 and 48 h, urine and blood plasma)

BMI-adjusted adipose tissue volumes exhibit depot-specific and divergent associations with cardiometabolic diseases